.. BioElectronics files Form 10K with Exchange and Securities Commission BioElectronics Corp. , the maker of inexpensive, disposable drug-free anti-inflammatory gadgets, today announced the completion of its complete yr audit and the filing of Type 10K with the Securities and Exchange Commission. BioElectronics is currently a completely reporting company. The procedure of providing complete transparency is essential to us and we be prepared to remain completely compliant and reporting continue, commented Andrew Whelan, CEO of BioElectronics Corp. The recent advancements at the Company have become exciting as our worldwide distribution is growing and as we continue steadily to sort out the clearance procedure with the U.S.ImaGenes, will provide all customers receiving Next Generation Sequencing data with a short-term permit for CLC Genomics Workbench for assembly and downstream sequence analyses. Director Bioinformatics & Solutions at imaGenes, Dr. Steffen Hennig, states, ‘We have been searching for a software system which we’re able to use to present our research results to our customers within an easy, coherent, and user-friendly way.